Dragon Pharma — Antiestrogens
7 antiestrogen products covering the complete on-cycle estrogen management spectrum — three aromatase inhibitors at different potency levels, one SHBG-binding androgenic support compound, and two SERMs for gynecomastia prevention and receptor-level estrogen blockade.
Antiestrogens
Showing 1–7 of 7 results
Dragon Pharma Antiestrogens — AI, SERM and SHBG Support
Estrogen management is an essential component of any AAS cycle involving aromatising compounds. Dragon Pharma's antiestrogen range covers the three pharmacologically distinct approaches: aromatase inhibition (reducing estrogen production at source), selective estrogen receptor modulation (blocking estrogen at tissue-specific receptors), and SHBG displacement (increasing free androgen fraction while reducing relative estrogenic influence). All seven products are independently third-party tested.
Aromatase Inhibitors — Three Potency Levels
Three AI compounds covering the full estrogen suppression spectrum. Arimidex (Anastrozole) is the standard first-line on-cycle AI — non-steroidal, reversible competitive inhibitor, approximately 85% estrogen suppression at 1mg/day; the appropriate choice for most testosterone-based cycles. Aromasin (Exemestane) is the steroidal irreversible AI — suicide substrate mechanism, 85-95% suppression, mild androgenic activity, preferred for PCT compatibility and bone density preservation. Femara (Letrozole) is the most potent AI available — 98-99% estrogen suppression at 2.5mg/day, reserved for high-aromatising cycles and gynecomastia reversal protocols where Anastrozole's ceiling is insufficient.
Proviron — SHBG Binding and Androgenic Support
Proviron (Mesterolone) occupies a unique position in this category — it is not an aromatase inhibitor and not a SERM, but produces indirect anti-estrogenic effects through two mechanisms: high-affinity SHBG binding that displaces testosterone and other AAS into the free (biologically active) fraction; and DHT-derived androgenic activity that improves the androgenic:estrogenic balance. Crucially, Proviron uses C1-methylation rather than 17-alpha-alkylation — making it the only oral androgen with zero hepatotoxicity, suitable for full-cycle duration use without hepatic concern.
SERMs — Receptor-Level Estrogen Blockade
Toremifene (Fareston) is the third-generation SERM — structurally similar to Tamoxifen but with chlorination that eliminates the genotoxic epoxide metabolites produced by Tamoxifen's hepatic metabolism. FDA-approved for breast cancer and studied specifically in men in the Phase III REDEEM trial at 20mg/day — the only SERM with completed Phase III data in a male population. Nolvadex (Tamoxifen) is the first-generation SERM reference standard — its primary activity is mediated through Endoxifen (active metabolite, 100× more potent than parent), with ERα antagonism in breast tissue and the HPG axis making it effective for both on-cycle gynecomastia prevention and PCT.
AI vs SERM — Choosing the Right Approach
Aromatase inhibitors and SERMs address estrogen through different mechanisms and are not interchangeable. AIs reduce estrogen production — systemic estrogen levels fall, addressing water retention, blood pressure and mood effects alongside gynecomastia prevention. SERMs block estrogen receptors in specific tissues (breast, HPG axis) without reducing circulating estrogen — effective for gynecomastia prevention and PCT but not for managing water retention or blood pressure from high estrogen. For most on-cycle use: AI for systemic estrogen control; SERM added specifically when gynecomastia protection beyond AI coverage is needed, or when Anadrol's non-aromatase estrogenic mechanism requires receptor-level blockade that AIs cannot provide.
Frequently Asked Questions
All three are aromatase inhibitors but differ in mechanism and potency. Anastrozole and Letrozole are non-steroidal reversible inhibitors — they occupy the aromatase active site competitively and their effect follows blood level curve. Exemestane is steroidal and irreversible — a suicide substrate that permanently deactivates aromatase molecules; its effect persists beyond its half-life. Potency: Letrozole (~98-99% suppression) > Exemestane (~85-95%) ≈ Anastrozole (~85%). For standard cycles: Anastrozole or Exemestane. For high-aromatising cycles or gyno reversal: Letrozole.
Only on cycles involving aromatising compounds. Testosterone, Nandrolone and Boldenone aromatise and typically require AI management. Trenbolone, Masteron, Primobolan, Winstrol, Anavar and DHB do not aromatise — AI is not needed for the estrogenic side effect profile of these compounds. Over-suppressing estrogen with AI on non-aromatising cycles causes estrogen crash — joint pain, low libido, fatigue and negative lipid effects. Blood panel estradiol monitoring is the most reliable guide to AI dosing.
Aromasin (Exemestane) is generally preferred for PCT for two reasons: its androgenic activity is beneficial during HPG recovery; and its irreversible mechanism means it continues working after its last dose as the body synthesises new aromatase enzyme — providing ongoing estrogen control without requiring continued dosing. Additionally, Anastrozole's blood levels are reduced by Tamoxifen's enzyme induction (CYP3A4), making Anastrozole a less reliable combination with Nolvadex — Exemestane is not affected by this interaction.
Proviron (Mesterolone) is placed in antiestrogens because of its indirect anti-estrogenic effects — primarily through high-affinity SHBG binding that frees bound testosterone and other AAS into the active fraction, improving the androgenic:estrogenic ratio. It does not inhibit aromatase and does not block estrogen receptors. Its other key property is being the only oral androgen without 17-alpha-alkylation — C1-methylation means zero hepatotoxicity, making it safe for full-cycle duration use alongside other compounds.
Letrozole suppresses estrogen by ~98-99% — far more than needed for standard cycle management. Estrogen is essential for bone density, cardiovascular health, libido, mood and joint function in men. Suppressing it to near-zero produces estrogen crash: severe joint pain, fatigue, depression, zero libido. Letrozole at full 2.5mg/day is appropriate for breast cancer treatment where maximum suppression is the goal — for AAS users, doses of 0.25-0.5mg every 2-3 days are more appropriate, and blood panel E2 monitoring is essential. Standard cycles are better managed with Anastrozole or Exemestane; Letrozole is reserved for high-aromatising cycles and gynecomastia reversal.